PCIA
VKTX icon

Prime Capital Investment Advisors’s Viking Therapeutics VKTX Stock Holding History

Prime Capital Investment Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Buy
11,343
+5,518
+95% +$177K ﹤0.01% 764
2025
Q4 		$205K Buy
+5,825
New +$206K ﹤0.01% 961
2024
Q4 		– Sell
-3,719
Closed -$235K – 973
2024
Q3 		$235K Buy
+3,719
New +$218K ﹤0.01% 807
2024
Q2 		– Sell
-2,578
Closed -$211K – 1039
2024
Q1 		$211K Buy
+2,578
New +$115K ﹤0.01% 912

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Prime Capital Investment Advisors's VKTX Position: Q1 2026 in Review

Prime Capital Investment Advisors increased its Viking Therapeutics (VKTX) stake by 95% in Q1 2026, buying an estimated $177K and bringing the position to 11,343 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #764.

Prime Capital Investment Advisors first reported a position in VKTX in Q1 2024 and has held it in 4 quarters since. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Prime Capital Investment Advisors held 11,343 shares of Viking Therapeutics worth $369K as of Q1 2026.
  • Prime Capital Investment Advisors bought 5,518 Viking Therapeutics shares in Q1 2026, an estimated $177K.
  • Viking Therapeutics made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #764 holding.
  • Prime Capital Investment Advisors first reported a position in Viking Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.